Skip to Main Content

Paper Details

I148M variant in PNPLA3 reduces central adiposity and metabolic disease risks while increasing nonalcoholic fatty liver disease.
Liver Int
28
2015
G, I148M, I148M variant, NAFLD, PNPLA3, cell types, hepatic steatosis, in PNPLA, insulin, metabolic disease, metabolic diseases, nonalcoholic fatty liver disease, participants, rs738409, rs738409-, triglycerides
Adult, Body Mass Index, Genetic Predisposition to Disease, Humans, Insulin Resistance, Lipase, Liver, Male, Membrane Proteins, Metabolic Diseases, Middle Aged, Non-alcoholic Fatty Liver Disease, Obesity, Abdominal, Polymorphism, Single Nucleotide, Republic of Korea, Triglycerides
Author NameAffiliation
Jin-Ho ParkBoston Children's Hospital
Jin-Ho ParkSeoul National University Hospital
Belong ChoSeoul National University Hospital
Hyuktae KwonHealthcare Research Institute, Seoul National University Hospital Healthcare System Gangnam Center
Daria PrilutskyCenter for Biomedical Informatics, Harvard Medical School
Jae Moon YunSeoul National University Hospital
Ho-Chun ChoiSeoul National University Hospital
Kyu-Baek HwangSoongsil University
In-Hee LeeSamsung Genome Institute, Institute for Refractory Cancer Research, Samsung Medical Center
In-Hee LeeSamsung Genome Institute, Institute for Refractory Cancer Research, Samsung Medical Center
Jong-Il KimGenomic Medicine Institute, Medical Research Center, Seoul National University
Jong-Il KimSeoul National University College of Medicine
Sek Won KongBoston Children's Hospital
Sek Won KongHarvard Medical School
  • 1 - 14

Datasets

Release 1.2